Home・Aktien・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Geschlossen

10.5 -1.5

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

10.37

Max

10.53

Schlüsselkennzahlen
By Trading Economics
Einkommen	-4.3M -18M
EPS	-0.19
Angestellte	37
EBITDA	-5.3M -17M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+180.15% upside

Dividenden
By Acuity
Nächstes Ergebnis	3. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-313M 812M
Vorheriger Eröffnungskurs	12
Vorheriger Schlusskurs	10.5

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

25. Okt. 2026, 23:51 UTC

GBP/AUD is advancing as trading resumes for the new week, showing notable upward movement since Friday's close amid a risk-off sentiment in U.S. markets.

25. Okt. 2026, 23:51 UTC

The EUR/NZD is gaining slightly in early trading, reflecting a modest advance since Friday's close amid fluctuations and below its 20-day moving average.

25. Okt. 2026, 23:51 UTC

Correlated Moves

Cardano is declining, continuing a trend seen in the broader cryptocurrency market, with Ethereum also trading lower since the previous close.

25. Okt. 2026, 23:51 UTC

Correlated Moves

Avalanche is trading lower, continuing a downward trend amid a broader market decline, influenced by falling Ethereum prices and rising oil prices.

25. Okt. 2026, 23:51 UTC

News

Bitcoin continues to decline, influenced by geopolitical tensions and significant investments, including $800K from Grant Cardone and a $3 billion plan from Strive.

25. Okt. 2026, 23:51 UTC

News

Ethereum is declining amid ongoing geopolitical tensions in the Middle East, contributing to market volatility and impacting investor sentiment toward cryptocurrencies.

25. Okt. 2026, 23:51 UTC

News

Bitcoin continues to decline, influenced by geopolitical tensions and significant investments, including Grant Cardone's $800K purchase and Strive's $3B acquisition plan.

25. Okt. 2026, 23:42 UTC

Upcoming Q3 Employment Cost Index Release on October 30, 2026, Expected to Influence Federal Reserve Policy Amid Rising Wage Concerns.

25. Okt. 2026, 23:42 UTC

Employment Cost Index for Q3 2026 set to rise by 0.8% amid cautious market sentiment, influencing Federal Reserve policy decisions.

25. Okt. 2026, 23:42 UTC

Upcoming Employment Cost Index Release on October 30, 2026, May Influence Economic Sentiment Amidst Cautious Market Conditions.

25. Okt. 2026, 23:42 UTC

Canada's September 2026 GDP growth expected at 0.2% amid cautious economic sentiment and trade tensions with the U.S.

25. Okt. 2026, 23:42 UTC

South Korea's Exports Surge 83.5% YoY in September, Anticipation Builds for November Data Amid Global Economic Pressures

25. Okt. 2026, 23:41 UTC

Macro News

The EUR/USD is trading slightly higher as the week begins, amid rising crude oil prices and geopolitical tensions affecting global economic conditions.

25. Okt. 2026, 23:41 UTC

The EUR/JPY is trading higher in early activity for the new week, despite settling slightly lower from a notable high reached earlier.

25. Okt. 2026, 23:41 UTC

GBP/CAD is gaining slightly in early trading, reflecting a modest upward movement since Friday's close while remaining near the lower end of its one-month range.

25. Okt. 2026, 23:31 UTC

Macro News

The AUD/USD is trading slightly lower as concerns about rising inflation expectations and geopolitical tensions contribute to market volatility at the start of the new trading week.

25. Okt. 2026, 23:31 UTC

Australia's Q3 2026 Producer Price Inflation set for release on October 30, with a modest forecasted rise of just 0.01% amid cautious market sentiment.

25. Okt. 2026, 23:31 UTC

U.S. Building Permits MoM Final for September 2026 Expected to Decline Slightly by -0.002% Amid Cautious Market Sentiment

25. Okt. 2026, 23:31 UTC

The EUR/CAD is advancing in early trading.

25. Okt. 2026, 23:31 UTC

News

Ethereum is trading lower, continuing a downward trend since Saturday's close, amid a broader decline in major U.S. stock indices and rising oil prices.

25. Okt. 2026, 23:31 UTC

Macro News

Ethereum is declining amid ongoing geopolitical tensions in the Middle East, impacting energy prices and contributing to market volatility.

25. Okt. 2026, 23:31 UTC

Macro News

News

Bitcoin is experiencing a modest decline as Grant Cardone invests $800K and Strive announces a $3 billion plan to acquire more BTC amid market volatility.

25. Okt. 2026, 23:22 UTC

The CHF/JPY currency pair is trading higher at the start of the new week.

25. Okt. 2026, 23:21 UTC

Core PCE Price Index Release on October 29 Expected to Show 0.3% Increase Amid Cautious Market Sentiment on Inflation Data

25. Okt. 2026, 23:21 UTC

US Personal Income Data Release on October 29, 2026 Expected to Show Modest Growth Amid Cautious Market Sentiment

25. Okt. 2026, 23:21 UTC

Upcoming PCE Price Index Release on October 29 Sparks Caution Among Investors Amid Rising Oil Prices and Inflation Concerns.

25. Okt. 2026, 23:21 UTC

U.S. GDP Deflator Forecasts 3.5% Increase for Q3 2026 Amid Economic Volatility and Geopolitical Tensions

25. Okt. 2026, 23:21 UTC

U.S. PCE Price Index Expected to Rise 0.5% on October 29 Amid Cautious Market Sentiment and Inflation Concerns

25. Okt. 2026, 23:21 UTC

U.S. Q3 2026 GDP Growth Rate Release on October 29 Forecasted at 3.2%, Amid Cautious Optimism and Economic Concerns

25. Okt. 2026, 23:21 UTC

US Personal Spending Expected to Rise 0.3% in September Amid Economic Uncertainties and Geopolitical Tensions

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

180.15% Vorteil

12-Monats-Prognose

Durchschnitt 29.5 USD 180.15%

Hoch 33 USD

Tief 27 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

Buy

Halten

Sell

Basierend auf 4 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Corvus Pharmaceuticals Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.